Alanine aminotransferase (ALT) activity assessment is a cornerstone laboratory test for evaluating hepatocellular injury and liver function in both clinical diagnostics and preclinical research. This technical article describes the enzymatic basis of ALT, accepted sample types, IFCC-aligned testing methods, quality control considerations, and practical applications in drug development, toxicology, and patient care. Use this guide to standardize ALT activity measurement and interpret results with confidence.
Technical Overview
Alanine aminotransferase (ALT, EC 2.6.1.2), historically referred to as serum glutamate pyruvate transaminase (SGPT or GPT), is a pyridoxal phosphate-dependent enzyme that catalyzes the reversible transfer of an amino group from L-alanine to alpha-ketoglutarate, producing pyruvate and L-glutamate. Because ALT is concentrated predominantly in the cytosol of hepatocytes, its appearance in the bloodstream at elevated concentrations is widely regarded as the most sensitive and specific biochemical marker of hepatocellular damage.
ALT activity assessment quantifies the catalytic capacity of the enzyme in biological fluids, most commonly serum or plasma, and reports results in units per liter (U/L), where one unit corresponds to the conversion of one micromole of substrate per minute under defined assay conditions. The plasma half-life of ALT is approximately 40 to 50 hours, which makes serial monitoring clinically useful for tracking the onset, progression, and resolution of hepatic injury.
- Primary reaction: L-alanine + alpha-ketoglutarate is converted to pyruvate + L-glutamate under ALT catalysis
- Principal tissue source: liver cytosol, with lower concentrations in kidney, skeletal muscle, and myocardium
- Isoforms: cytosolic ALT1 and mitochondrial ALT2, encoded by separate genes (GPT and GPT2)
- Typical adult reference intervals: approximately 7 to 40 U/L, varying by sex, age, method, and laboratory definition
- Core diagnostic role: detection and monitoring of acute and chronic hepatocellular injury
Testing Samples
Serum
Serum collected from a plain tube (with or without separator gel) is the preferred specimen for routine ALT activity determination. Serum avoids anticoagulant-related interference and is compatible with all major automated chemistry platforms. Venous blood should be allowed to clot completely before centrifugation, and grossly hemolyzed, lipemic, or icteric samples should be flagged because they may compromise photometric accuracy at 340 nm.
Plasma
Heparinized plasma is an acceptable alternative and yields results generally comparable to serum. EDTA plasma may also be used on validated systems, while citrate and oxalate plasma should be avoided unless method-specific validation demonstrates equivalence, because anticoagulants can dilute the sample or inhibit enzyme activity. Laboratories must confirm tube compatibility with the reagent manufacturer.
Tissue Homogenates and Cell Lysates
In preclinical and biomedical research, ALT activity can be measured in liver tissue homogenates, primary hepatocyte cultures, and conditioned media to quantify cellular injury in vitro. Samples require controlled lysis, clarification by centrifugation, and dilution within the validated linear range of the assay, with results frequently normalized to total protein or tissue mass.
Sample Handling and Stability
ALT is relatively stable compared with many other enzymes. Serum or plasma remains suitable for analysis for at least 24 hours at 2 to 8 °C, and activity is preserved for several weeks at -20 °C or below. Repeated freeze-thaw cycles should be minimized, samples should be mixed gently after thawing, and strenuous exercise or intramuscular injection shortly before collection should be avoided to prevent transient activity elevations of muscular origin.
Testing Items
The core deliverable of this assessment is the quantitative ALT catalytic activity of the submitted specimen, interpreted against method-specific reference intervals. Standard testing panels and reported items include the following:
- ALT activity in serum or plasma, expressed in U/L (convertible to microkatals per liter)
- Interpretation against age- and sex-adjusted reference intervals
- Review of hemolysis, icterus, and lipemia indices for sample suitability
- Optional paired AST activity with calculation of the De Ritis ratio (AST/ALT)
- Optional repeat and dilution testing for specimens exceeding the analytical measurement range
- Trend reporting for serial specimens submitted within a monitoring protocol
Testing Methods
IFCC Reference Procedure at 37 °C
The internationally recognized method for ALT activity is the IFCC reference procedure, performed at 37 °C with pyridoxal-5-phosphate (P-5-P) activation. The assay employs a coupled enzyme system: ALT converts L-alanine and alpha-ketoglutarate to pyruvate and glutamate, and exogenous lactate dehydrogenase (LDH) reduces the pyruvate to lactate while oxidizing NADH to NAD. The rate of decrease in NADH absorbance, monitored continuously at 339 to 340 nm, is directly proportional to ALT activity. The specimen is preincubated with buffer, L-alanine, NADH, LDH, and P-5-P to consume endogenous pyruvate, and the reaction is initiated by adding alpha-ketoglutarate after the lag phase.
Conventional Kinetic UV Assays
Most automated clinical chemistry analyzers implement simplified kinetic versions of the coupled LDH/NADH reaction, either with or without P-5-P supplementation. Assays without P-5-P may underestimate activity in specimens from patients with vitamin B6 deficiency or chronic liver disease, and results from different reagent systems should be harmonized through method comparison. Enzyme activity is calculated from the absorbance change per minute multiplied by a factor derived from the sample-to-total volume ratio, the molar absorptivity of NADH, and the optical path length. Specimens exceeding the validated linear range, commonly above 400 to 600 U/L depending on the platform, are diluted and re-assayed.
Colorimetric Endpoint Methods
Legacy techniques, such as the Reitman-Frankel procedure, detect the pyruvate formed during a fixed incubation by derivatization with 2,4-dinitrophenylhydrazine and measurement of the resulting hydrazone in alkaline solution. These endpoint methods lack the precision of continuous-monitoring assays and are now largely restricted to resource-limited settings or historical data comparison.
Quality Control and Interference Management
Each analytical run should include calibrators and at least two levels of quality control materials spanning the clinical decision range, with acceptability judged by Westgard-style rules or equivalent laboratory protocols. Proficiency testing participation, lot-to-lot verification, and periodic linearity checks are expected elements of a compliant quality system. Significant analytical and biological considerations include the following:
- Hemolysis: modest direct interference for ALT, but flagged because coexisting AST elevation may be masked or magnified
- Lipemia: light scattering at 340 nm can bias kinetic readings; ultracentrifugation or blanking may be required
- High bilirubin: potential spectral interference at high concentrations on some systems
- In vivo effects: medications such as statins, isoniazid, NSAIDs, antibiotics, and herbal preparations can cause genuine ALT elevation rather than analytical interference
- Extrahepatic sources: intense exercise, muscle injury, hyperthyroidism, and celiac disease may raise ALT independently of liver disease
Applications
Clinical Diagnostics
ALT activity is a first-line test in the evaluation of suspected liver disease. Marked elevations, often exceeding ten times the upper reference limit, are characteristic of acute viral hepatitis, ischemic hepatopathy, and toxic or drug-induced liver injury, whereas mild to moderate persistent elevations are typical of chronic hepatitis, nonalcoholic fatty liver disease, and early cirrhosis. Serial ALT measurement guides treatment response in chronic viral hepatitis and supports longitudinal surveillance of patients receiving hepatotoxic therapies.
Drug Development and Preclinical Toxicology
In GLP-compliant repeat-dose toxicology studies, plasma ALT activity in rodents and non-rodents is a mandated safety endpoint for identifying hepatocellular injury before clinical exposure. Combined interpretation with aspartate aminotransferase, alkaline phosphatase, bilirubin, and histopathology enables the industry-standard evaluation of drug-induced liver injury risk and informs dose selection and clinical monitoring plans in first-in-human studies.
Blood Donor Screening
ALT screening of donated blood was historically used to reduce the risk of transfusion-transmitted non-A, non-B hepatitis before the availability of hepatitis C antibody and nucleic acid testing. Some blood services continue to apply ALT thresholds as a surrogate marker of occult liver disease or unreported risk behavior, in combination with infectious disease assays.
Epidemiological and Metabolic Research
Population studies employ ALT activity as a noninvasive indicator of metabolic dysfunction-associated steatotic liver disease, insulin resistance, and cardiovascular risk. Standardized ALT measurement underpins cohort analyses, lifestyle and pharmacologic intervention trials, and the derivation of upper reference limits optimized for disease sensitivity rather than purely statistical definitions.
FAQ
What does an elevated ALT level mean?
An elevated ALT level indicates leakage of the enzyme from damaged hepatocytes and therefore suggests hepatocellular injury. The magnitude and pattern of elevation, interpreted together with AST, alkaline phosphatase, bilirubin, clinical history, and imaging, help distinguish viral, toxic, ischemic, autoimmune, and metabolic causes.
What is the normal reference range for ALT activity?
Typical adult reference intervals are approximately 7 to 40 U/L, with lower sex-specific upper limits often applied in hepatology practice, for example around 33 U/L for men and 25 U/L for women. Exact limits vary by method, temperature, population, and laboratory, so results should always be interpreted against the reporting laboratory's validated intervals.
Which sample type is preferred, serum or plasma?
Serum is the preferred specimen because it is free of anticoagulant effects and is universally compatible with automated platforms. Heparinized plasma is acceptable on validated systems, while EDTA plasma requires method-specific verification and citrate or oxalate plasma is generally discouraged.
How long are ALT samples stable?
ALT activity in separated serum or plasma is stable for at least 24 hours at 2 to 8 °C and for several weeks frozen at -20 °C or colder. Freeze-thaw cycles should be minimized, and unseparated clotted tubes should be processed promptly to prevent in vitro changes.
Can ALT distinguish liver injury from muscle injury?
ALT is considerably more liver-specific than AST, but marked muscle damage can also raise ALT. When the source of elevation is unclear, paired measurement of creatine kinase and the AST/ALT De Ritis ratio helps discriminate hepatic from muscular origin.
Why do some methods include pyridoxal-5-phosphate?
Pyridoxal-5-phosphate is the essential coenzyme of ALT, and a subset of patients, particularly those with malnutrition or advanced liver disease, have insufficient endogenous coenzyme saturation. Including P-5-P in the reagent, as specified by the IFCC reference procedure, ensures full enzyme activation and improves accuracy and inter-laboratory comparability.